Antiplatelet Management Before Total Knee Replacement
For elective total knee replacement, aspirin (ASA) should be stopped ≤7 days before surgery, clopidogrel and ticagrelor should be discontinued 5 days before surgery, and prasugrel should be stopped 7 days before surgery 1, 2, 3.
Specific Timing by Agent
Aspirin (ASA)
- Stop ≤7 days before surgery (not the traditional 7-10 days) 1
- For patients at high cardiovascular risk, aspirin may be continued through surgery with only modest increased bleeding risk 2, 3
- Research shows discontinuing ASA ≥7 days preoperatively reduces hematomas, emergency department visits, readmissions, and 90-day complications compared to stopping closer to surgery 4
P2Y12 Inhibitors (Clopidogrel, Ticagrelor, Prasugrel)
- Clopidogrel: Stop 5 days before surgery 1, 2, 3
- Ticagrelor: Stop 3-5 days before surgery 1
- Prasugrel: Stop 7 days before surgery 2, 3
The 2022 ACCP guidelines represent the most current evidence and suggest shorter interruption periods than older recommendations (which suggested 7-10 days for all P2Y12 inhibitors) 1.
Key Clinical Considerations
High-Risk Scenarios
If the patient has coronary stents placed within the last 6-12 weeks, either continue both antiplatelet agents or stop only one agent rather than stopping both 1. This balances stent thrombosis risk against surgical bleeding.
Urgent Surgery Exception
For urgent (non-elective) TKR, clopidogrel and ticagrelor can be stopped as little as 24 hours before surgery to reduce major bleeding, though this increases transfusion risk 2.
Resumption Timing
Resume antiplatelet drugs ≤24 hours after surgery at the maintenance dose 1. This typically means the evening of surgery or the next morning, assuming adequate hemostasis.
Common Pitfalls to Avoid
Don't routinely stop aspirin in all patients: The evidence shows aspirin can often be continued safely, particularly in patients with established cardiovascular disease where the thrombotic risk outweighs modest bleeding increases 2, 3
Don't use the outdated 7-10 day rule for all antiplatelets: The most recent 2022 guidelines support shorter interruption periods, particularly for ticagrelor (3-5 days) 1
Don't delay resumption beyond 24 hours: Early resumption (within 24 hours) is recommended unless there are specific bleeding concerns 1
Don't use platelet function testing routinely: This is not recommended for guiding perioperative management in elective TKR 1
Evidence Quality Note
While these recommendations come from high-quality guidelines 1, 2, 3, the certainty of evidence is generally low to very low, reflecting the lack of large randomized trials specifically in TKR populations. The recommendations are conditional and based primarily on pharmacokinetic data, observational studies, and extrapolation from cardiac surgery literature. The 2022 ACCP guideline 1 represents the most current synthesis and suggests shorter interruption periods than previous guidelines, reflecting evolving understanding of antiplatelet pharmacology.